Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
10 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Pipeline Program Update Conference Call and Webcast
08 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
12 mai 2020 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
07 mai 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Provides Business Update Related to COVID-19 Pandemic
09 avr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
27 févr. 2020 16h15 HE
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
Otonomy to Present at Two Upcoming Investor Conferences
24 févr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
20 févr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
28 janv. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
23 janv. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...